Celularity Inc
CELU
Detailliertes Diagramm anzeigen
1.840USD
+0.120+6.98%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
45.28MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+6.98%
5 Tage
-4.66%
1 Monat
-13.62%
6 Monate
+16.09%
Seit Jahresbeginn
-11.54%
1 Jahr
+18.71%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Celularity Inc
Währung: USD Aktualisiert: 2025-11-05Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ stabil. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Celularity Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Kaufen
Aktuelles Rating
6.000
Kursziel
+248.84%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Celularity Inc Highlights
HöhepunkteRisiko
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
performance_growth_high
performance_growth_high_desc%!(EXTRA string=201.64%)
performance_growth_period
performance_growth_period_desc%!(EXTRA string=54.22M)
valuation_reasonable
valuation_reasonable_desc%!(EXTRA string=PE, string=-0.58)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=3.54M, string=13.74%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=500.13K)
activity_decrease
activity_decrease_desc%!(EXTRA string=-0.90)
Celularity Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Celularity Inc Informationen
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
BörsenkürzelCELU
UnternehmenCelularity Inc
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Websitehttps://celularity.com/
Verwandte Finanzinstrumente
+2.09%
-0.46%
+0.41%
-1.07%
+0.39%
+0.63%
+7.81%
+0.44%
-0.34%
+1.28%
-0.22%
-1.11%
+0.31%
+1.93%
-0.28%
-0.11%
0.00%
+2.58%
+2.62%
-3.19%Beliebte Symbole
